help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by OGA, T.
Right arrow Articles by IZUMI, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by OGA, T.
Right arrow Articles by IZUMI, T.

Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 1897-1901

The Effects of Oxitropium Bromide on Exercise Performance in Patients with Stable Chronic Obstructive Pulmonary Disease
A Comparison of Three Different Exercise Tests

TORU OGA, KOICHI NISHIMURA, MITSUHIRO TSUKINO, TAKASHI HAJIRO, AKIHIKO IKEDA, and TAKATERU IZUMI

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

The purpose of the present study was to compare the characteristics of three different exercise tests in evaluating the effects of oxitropium bromide on exercise performance. Thirty-eight males with stable chronic obstructive pulmonary disease (COPD) (FEV1 = 40.8 ± 16.5% predicted; mean ± SD) completed randomized, double-blind, placebo-controlled, crossover studies for each exercise test. The exercise tests were performed 60 min after the inhalation of either oxitropium bromide 400 µg or placebo. The patients performed 6-min walking tests (6MWT) on Days 1 and 2, progressive cycle ergometry (PCE) on Days 3 and 4, and cycle endurance tests at 80% of the maximal workload of PCE on Days 5 and 6. Spirometry was conducted before and at 45 and 90 min after the inhalation. Oxitropium bromide significantly increased FEV1 as compared with placebo. Oxitropium bromide increased the endurance time significantly, by 19% (p < 0.001), and caused a small but significant increase in the 6-min walking distance by 1% (p < 0.05), but induced no significant increase in maximal oxygen consumption (V O2max) in PCE. The responses in these three exercise tests were different, and we conclude that the endurance test was the most sensitive in detecting the effects of inhaled anticholinergic agents on exercise performance in patients with stable COPD. An endurance procedure may be performed to detect clinical changes in evaluating the effects of oxitropium bromide on exercise performance.




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Casaburi
Boosting the Effectiveness of Rehabilitative Exercise Training
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 805 - 806.
[Full Text] [PDF]


Home page
Eur Respir JHome page
C. Brouillard, V. Pepin, J. Milot, Y. Lacasse, and F. Maltais
Endurance shuttle walking test: responsiveness to salmeterol in COPD
Eur. Respir. J., March 1, 2008; 31(3): 579 - 584.
[Abstract] [Full Text] [PDF]


Home page
Chronic Respiratory DiseaseHome page
S. Jenkins
Which is the best exercise test to assess therapeutic intervention in COPD?
Chronic Respiratory Disease, February 1, 2008; 5(1): 3 - 5.
[PDF]


Home page
Eur Respir JHome page
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
D. E. O'Donnell, R. B. Banzett, V. Carrieri-Kohlman, R. Casaburi, P. W. Davenport, S. C. Gandevia, A. F. Gelb, D. A. Mahler, and K. A. Webb
Pathophysiology of Dyspnea in Chronic Obstructive Pulmonary Disease: A Roundtable
Proceedings of the ATS, May 1, 2007; 4(2): 145 - 168.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. J. Serisier, A. D. Coates, and S. D. Bowler
Effect of Albuterol on Maximal Exercise Capacity in Cystic Fibrosis
Chest, April 1, 2007; 131(4): 1181 - 1187.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M D L Morgan and S J Singh
Assessing the exercise response to a bronchodilator in COPD: time to get off your bike?
Thorax, April 1, 2007; 62(4): 281 - 283.
[Full Text] [PDF]


Home page
ThoraxHome page
V. Pepin, J. Brodeur, Y. Lacasse, J. Milot, P. LeBlanc, F. Whittom, and F. Maltais
Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease
Thorax, April 1, 2007; 62(4): 291 - 298.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al.
Recommendations on the use of exercise testing in clinical practice
Eur. Respir. J., January 1, 2007; 29(1): 185 - 209.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. A. Mahler, L. A. Waterman, J. Ward, and J. C. Baird
Responsiveness of Patient-Reported Breathlessness During Exercise in Persistent Asthma
Chest, January 1, 2007; 131(1): 195 - 200.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. L. P. Albuquerque, L. E. Nery, D. S. Villaca, T. Y. S. Machado, C. C. Oliveira, A. T. Paes, and J. A. Neder
Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III
Eur. Respir. J., November 1, 2006; 28(5): 939 - 944.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. E. O'Donnell, F. Sciurba, B. Celli, D. A. Mahler, K. A. Webb, C. J. Kalberg, and K. Knobil
Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD.
Chest, September 1, 2006; 130(3): 647 - 656.
[Abstract] [Full Text] [PDF]


Home page
Chronic Respiratory DiseaseHome page
S A Ward
Exercise testing needs to be comprehensive
Chronic Respiratory Disease, April 1, 2006; 3(2): 109 - 109.
[PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
V. Pepin, D. Saey, F. Whittom, P. LeBlanc, and F. Maltais
Walking versus Cycling: Sensitivity to Bronchodilation in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1517 - 1522.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
W. Vincken
Bronchodilator treatment of stable COPD: long-acting anticholinergics
Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. Oga, K. Nishimura, M. Tsukino, S. Sato, T. Hajiro, and M. Mishima
Exercise Capacity Deterioration in Patients With COPD: Longitudinal Evaluation Over 5 Years
Chest, July 1, 2005; 128(1): 62 - 69.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer
Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38.
[Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
T. Higenbottam
Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease: A Case for Treatment
Proceedings of the ATS, April 1, 2005; 2(1): 12 - 19.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. J. Oudiz and K. Wasserman
Clinical efficacy of sildenafil in primary pulmonary hypertension
J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2256 - 2256.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B.K.S. Sastry and C. Narasimhan
Reply
J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2256 - 2257.
[Full Text] [PDF]


Home page
Eur Respir JHome page
D.E. O'Donnell, N. Voduc, M. Fitzpatrick, and K.A. Webb
Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease
Eur. Respir. J., July 1, 2004; 24(1): 86 - 94.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D.E. O'Donnell, T. Fluge, F. Gerken, A. Hamilton, K. Webb, B. Aguilaniu, B. Make, and H. Magnussen
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
Eur. Respir. J., June 1, 2004; 23(6): 832 - 840.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K.-C. Ong, A.-C. Kor, W.-F. Chong, A. Earnest, and Y.-T. Wang
Effects of Inhaled Furosemide on Exertional Dyspnea in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., May 1, 2004; 169(9): 1028 - 1033.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. Oga, K. Nishimura, M. Tsukino, S. Sato, T. Hajiro, and M. Mishima
A Comparison of the Effects of Salbutamol and Ipratropium Bromide on Exercise Endurance in Patients With COPD
Chest, June 1, 2003; 123(6): 1810 - 1816.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. Oga, K. Nishimura, M. Tsukino, S. Sato, and T. Hajiro
Analysis of the Factors Related to Mortality in Chronic Obstructive Pulmonary Disease: Role of Exercise Capacity and Health Status
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 544 - 549.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
ATS/ACCP Statement on Cardiopulmonary Exercise Testing
Am. J. Respir. Crit. Care Med., January 15, 2003; 167(2): 211 - 277.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. V. Culpitt, C. de Matos, R. E. Russell, L. E. Donnelly, D. F. Rogers, and P. J. Barnes
Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1371 - 1376.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804.
[Full Text] [PDF]


Home page
Eur Respir JHome page
M.L. Ayers, R. Mejia, J. Ward, T. Lentine, and D.A. Mahler
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD
Eur. Respir. J., June 1, 2001; 17(6): 1132 - 1137.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society
  ATS State of the Art Course 2008